drugset / Trial / NCT01938378
Octaplas Pediatric Plasma Exchange Trial
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters in pediatric patients who require therapeutic plasma exchange.
Timeline
- Start
- 2015-04
- Primary completion
- 2019-01-27
- Completion
- 2019-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octaplas LG | Other / unclassified | 40 unknown | Intravenous |
| Subject | Octaplas LG | Other / unclassified | 60 unknown | Intravenous |
Indications
No indication recorded.